Liminatus Pharma, Inc. Class A Common Stock (LIMN)

• Market cap: $528M
• 1 day: 82.81%
• 5 days: -0.44%
• 1 month: 184.85%
• 3 months: 101.69%
• 6 months: 101.69%
• Year to date: 101.69%
• 1 year: 101.69%
• 5 years: 101.69%
• 10 years: 101.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.